SCHEMBL4199588

SCHEMBL4199588

COc1cc(-c2nc3ncccc3c(=O)n2NCc2ccc(Br)cc2)ccc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
NPSR1 Q6W5P4 4/20 0.46
MAPT P10636 4/20 0.46
HPGD P15428 2/20 0.44
HTT P42858 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
IDO1 P14902 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199190 0.91 KMT2A (0.49) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4187084 0.88 MAPT (0.56) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4235803 0.87 KMT2A (0.65) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4205033 0.82 MEN1 (0.47) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4199192 0.81 SMN1; SMN2 (0.48) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4188985 0.81 MAPT (0.46) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4239837 0.78 KMT2A (0.62) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4245014 0.78 KMT2A (0.62) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4245003 0.78 NPSR1 (0.69) MEN1POLBKMT2ANPSR1MAPT
SCHEMBL4233693 0.77 KMT2A (0.65) MEN1POLBKMT2ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 MEN1 4670/4885POLB 4715/4885KMT2A 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.